The agency is charged with boosting the profile of the firm, which bills itself as 'the only provider of custom-designed nanoparticle products and services to the pharma and biopharma community', among major pharmas' licensing executives.
Midatech wants to become the leading name in the appliance of nanotechnology in medicine and hopes its delivery technologies will eventually be used to treat major diseases.
It is developing a unique method via which in-vitro and in-vivo imaging and drug delivery can be achieved. The firm's name relates to atoms of gold it uses in the synthesis of bioactive nanoparticles.
Healthcare Solutions MD Sarah Rogers said: 'We are aiming to put Midatech on the map.'
The agency, which was hired without a competitive pitch, will promote Midatech at trade conferences such as the NSTI Nanotech event in Anaheim in May.
It will also promote Midatech at a further US trade event in June and BIOEurope in Dresden in November. The agency is also targeting vaccine makers and imaging companies through specialist media.